NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Dan Zhao
AD Scientific Index 2024
Others
Servier Pharmaceuticals - / United States
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Dan Zhao's MOST POPULAR ARTICLES
1-)
Vorasidenib in IDH1-or IDH2-mutant low-grade gliomaIK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ...New England Journal of Medicine 389 (7), 589-601, 20231622023
2-)
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLMA Sekeres, J Watts, A Radinoff, MA Sangerman, M Cerrano, PF Lopez, ...Leukemia 35 (7), 2119-2124, 2021952021
3-)
The microbiome composition of a man\'s penis predicts incident bacterial vaginosis in his female sex partner with high accuracySD Mehta, D Zhao, SJ Green, W Agingu, F Otieno, R Bhaumik, D Bhaumik, ...Frontiers in cellular and infection microbiology 10, 433, 2020582020
4-)
Phase II study of pevonedistat (P)+ azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low …L Ades, JM Watts, A Radinoff, M Arnan, M Cerrano, P Font Lopez, ...Journal of Clinical Oncology 38 (15_suppl), 7506-7506, 2020212020
5-)
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced …X Zhou, F Sedarati, DV Faller, D Zhao, HM Faessel, S Chowdhury, ...Investigational New Drugs 39, 488-498, 2021172021
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept